Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 390

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 390
---
370(68)(0.8)%  Amortization of intangible asset1515——%Total operating expenses30,24330,2394—%Loss from operations(30,243)(30,239)(4)—%Other income (expense)Interest income7631,631(868)(53.2)%Other income— 221 (221)(100.0)%Net loss$(29,480)$(28,387)$(1,093)3.9 %

Research and Development

The following table summarizes the components of research and development expenses for the periods indicated:

Six Months Ended June 30,Change20252024$%(in thousands, except percentages)Direct research and development expenses by program:atebimetinib (IMM-1-104)$9,427 $7,454 $1,973 26.5 %IMM-6-4151,902 2,160 (258)(11.9)%Other programs2,420 3,536 (1,116)(31.6)%Indirect research and development expenses:Employee-related costs6,053 6,687 (634)(9.5)%Stock-based compensation expense1,343 1,245 98 7.9 %Facilities and other expenses658 649 9 1.4 %Depreciation/amortization122 123 (1)(0.8)%Total research and development$21,925 $21,854 $71 0.3 %

Research and development expenses increased by approximately $0.1 million, or 0.3%, to approximately $21.9 million for the six months ended June 30, 2025 as compared to approximately $21.9 million for the six months ended June 30, 2024. The increase of approximately $0.1 million was primarily due to an increase of approximately $0.6 million related to direct research and development expenses, of which there was an approximately $2.0 million increase in expenses related to atebimetinib (IMM-1-104), offset by a $0.3 million decrease in expenses related to IMM-6-415 driven by decreased manufacturing and preclinical spend, and by a $1.1 million decrease in spend for earlier stage programs. The remaining variance was attributable to decreased indirect research and development costs of approximately $528 thousand, driven by a $0.6 million decrease associated with employee-related